ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Design of the GutHeart—targeting gut microbiota to treat heart failure—trial: a Phase II, randomized clinical trial

Permanent lenke
https://hdl.handle.net/10037/14069
DOI
https://doi.org/10.1002/ehf2.12332
Thumbnail
Åpne
article.pdf (370.8Kb)
Publisher's version (PDF)
Dato
2018-08-07
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Mayerhofer, Christiane Caroline; Awoyemi, Ayodeji Olawale; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hov, Johannes Espolin Roksund; Aukrust, Pål; Hovland, Anders; Lorenzo, Andrea; Halvorsen, Sigrun; Seljeflot, Ingebjørg; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar
Sammendrag

Aims: Heart failure (HF) is a multifactorial disease. Current treatments target only a fraction of the putative pathophysiological pathways. In patients with HF, reduced cardiac output and congestion cause increased gut wall permeability. It has been suggested that leakage of microbial products is detrimental to the heart, at least partly through activation of systemic inflammatory pathways, which again could promote gut leakage. Whether manipulating the gut microbiota can improve cardiac function in patients with HF remains unknown. We aim to evaluate the effect of drugs targeting the gut microbiota on left ventricular function, quality of life, and functional capacity, as well as on markers of gut leakage and inflammation, in stable patients with HF with reduced ejection fraction.

Methods and results: GutHeart is a randomized, open‐label, controlled trial. Four centres will randomize 150 patients with stable HF and a left ventricular ejection fraction <40% to receive the antibiotic rifaximin, the probiotic yeast Saccharomyces boulardii (ATCC 74012), or no treatment (control) in a 1:1:1 fashion. Treatment will last for 3 months. The primary endpoint is baseline‐adjusted left ventricular ejection fraction as measured by echocardiography after 3 months. A further follow‐up 6 months after randomization will be undertaken.

Conclusions: This trial is likely to give new insights into important disease processes involving the gut microbiota in HF patients, hereby leading to new potential therapeutic strategies to prevent and down‐regulate the inflammation seen in these patients.

Beskrivelse
Source at https://doi.org/10.1002/ehf2.12332. Licensed CC BY-NC-ND 4.0.
Forlag
Wiley Open Access
Sitering
Mayerhofer, C.C.K., Awoyemi, A.O., Moscavitch, S.D., Lappegård, K.T., Hov, J.R., Aukrust, P., ... Broch, K. (2018). Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial. ESC Heart Failure, 5, 978-985. https://doi.org/10.1002/ehf2.12332
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring